Ocugen (OCGN) Capital Expenditures (2014 - 2026)
Ocugen (OCGN) reported Capital Expenditures of $6000.0 for Q1 2026, down 62.5% on a YoY basis from $16000.0 in Q1 2025, and down 96.39% quarter-over-quarter from $166000.0 in Q4 2025.
Ocugen (OCGN) Capital Expenditures (2014 - 2026) Analysis & Trends
Ocugen has reported Capital Expenditures for 13 years, with the latest figure at $6000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 62.5% year-over-year to $6000.0; the trailing twelve-month figure through Mar 2026 stood at $175000.0 (down 94.22% YoY), and the FY2025 full-year result was $185000.0, down 94.53% from the prior year.
- Capital Expenditures for Q1 2026 stood at $6000.0, down from $166000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $3.4 million in Q3 2023, with the low at -$1.5 million in Q4 2022.
- Historically, Capital Expenditures has averaged $880176.5 across 5 years, with a median of $371000.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures slumped 892.71% — and 2023, when it soared 2414.17%.
- Ocugen's Capital Expenditures stood at -$1.5 million in 2022, then surged by 278.84% to $2.7 million in 2023, then plunged by 99.52% to $13000.0 in 2024, then surged by 1176.92% to $166000.0 in 2025, then tumbled by 96.39% to $6000.0 in 2026.
- The last three Capital Expenditures figures came in at $6000.0 (Q1 2026), $166000.0 (Q4 2025), and -$40000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 166,000.00 |
| Dec 31, 2025 | 166,000.00 |
| Sep 30, 2025 | -40,000.00 |
| Sep 30, 2025 | -40,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 507,000.00 |
| Sep 30, 2024 | 507,000.00 |
| Jun 30, 2024 | 2.49 Mn |
| Jun 30, 2024 | 2.49 Mn |
| Mar 31, 2024 | 371,000.00 |
| Mar 31, 2024 | 371,000.00 |
| Dec 31, 2023 | 2.72 Mn |
| Dec 31, 2023 | 2.72 Mn |